Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Characterizing Quality of Life Post-Deep Brain Stimulation (DBS) using EQ-5D-5L
Movement Disorders
P14 - Poster Session 14 (8:00 AM-9:00 AM)
3-014
To track the impact of DBS therapy from the patient‘s perspective on health-related quality of life over three years post initial implant using EQ-5D-5L index from Parkinson’s disease (PD) patients in the global Product Surveillance Registry (PSR).
The progressive nature of PD is marked by increased motor complications and disability over time which profoundly impacts quality of life. The EQ-5D-5L index is a standardized, generic self-reporting instrument evaluating the impact of treatment on health-related quality of life (QoL) and has been shown to be correlated with disease-specific QoL measures.The PSR is a global registry for DBS with inception in 2009.
A total of 359 therapy-naïve PD patients from the PSR with at least one paired EQ-5D-5L index score through 3 years post-implant were included (data cutoff date: April 30, 2019). EQ-5D-5L includes the domains of mobility, usual activities, self-care, pain/ discomfort, and anxiety/depression. The conversion of the five EQ-5D-5L dimensions to one EQ-5D-5L index value was done using the UK value set.  The EQ-5D-5L index score changes were calculated for patients with both baseline and follow-up observations only.

Mean age at enrollment was 61.9 years, 68.5% were male, and mean years from disease onset to DBS implant was 10.2 years. The EQ-5D index scores in patients with paired observations are ranging from -0.285 (worst) to 1 (best). EQ-5D-5L index scores improved by 0.125 (n=318, p<. 0001) at first 6/12-month follow-up, 0.078 at 2-year follow-up (n=249, p<. 0001), and 0.069 at 3-year follow-up (n=178, p<. 0001). The minimally important difference (MID) in the UK index score is estimated at 0.037.
Results from this  PSR population have demonstrated the sensitivity and usefulness of the EQ-5D-5L in real world settings on  determining  the impact of DBS on QoL. Significant sustained improvement in EQ-5D index score was shown through 3 years post-implant.
Authors/Disclosures
Mya C. Schiess, MD, FÂ鶹´«Ã½Ó³»­ (Univ of Texas-Houston Med School)
PRESENTER 		Dr. Schiess has nothing to disclose.
Leonard Verhagen Metman, MD, PhD (Northwestern University) Dr. Verhagen Metman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for AbbVie. Dr. Verhagen Metman has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Abbott. Dr. Verhagen Metman has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Mitsubishi Tanabe. Dr. Verhagen Metman has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Supernus. Dr. Verhagen Metman has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for AbbVie. Dr. Verhagen Metman has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Cerevel. Dr. Verhagen Metman has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Frontiers.
George M. Plotkin, MD, PhD The institution of Dr. Plotkin has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Medtronic.
Kenneth P. Martinez, MD (Neurology & Pain Specialty Center) The institution of Dr. Martinez has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Merz. The institution of Dr. Martinez has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Abbvie/Allergan. The institution of Dr. Martinez has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Revance. The institution of Dr. Martinez has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Argenx. The institution of Dr. Martinez has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Abbvie/Allergan. The institution of Dr. Martinez has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Merz. The institution of Dr. Martinez has received research support from Medtronic. The institution of Dr. Martinez has received research support from Abbvie/Allergan.
Fernando L. Pagan, MD, FÂ鶹´«Ã½Ó³»­ (Georgetown University Hospital Dept of Neurology) Dr. Pagan has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Acorda. Dr. Pagan has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Adamas. Dr. Pagan has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Amneal. Dr. Pagan has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Merz. Dr. Pagan has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Kyowa Kirin. Dr. Pagan has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sunovion. Dr. Pagan has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Teva. Dr. Pagan has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for US World Meds. Dr. Pagan has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Supernus. Dr. Pagan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Abbvie. Dr. Pagan has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Acorda. Dr. Pagan has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Adamas. Dr. Pagan has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Amneal. Dr. Pagan has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Sunovion. Dr. Pagan has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Teva. Dr. Pagan has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Neurocrine. Dr. Pagan has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Sunovion. Dr. Pagan has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Supernus. Dr. Pagan has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Journal of Clinical Parkinsonism and related Disorders. Dr. Pagan has stock in Keiferx. The institution of Dr. Pagan has received research support from US World Meds. The institution of Dr. Pagan has received research support from Novartis.
No disclosure on file